Daiichi Sankyo's Warfarin Substitute Shows Equivalence In Study
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's Lixian (edoxaban) substitute for six-decades-old warfarin as a blood-thinning drug has shown in clinical trials to be at least as effective and safe in preventing embolisms and strokes in abnormal heart-rhythm cases.